PerkinElmer, Inc. (PKI) Price Target Raised to $78.00 at Morgan Stanley

PerkinElmer, Inc. (NYSE:PKI) had its price objective boosted by Morgan Stanley from $77.00 to $78.00 in a research note issued to investors on Friday. The firm presently has an “overweight” rating on the medical research company’s stock. Morgan Stanley’s price objective points to a potential upside of 10.45% from the company’s current price.

A number of other analysts have also recently weighed in on the stock. Robert W. Baird increased their price target on shares of PerkinElmer from $75.00 to $78.00 and gave the stock an “outperform” rating in a research note on Friday. Citigroup Inc. reiterated a “buy” rating and issued a $80.00 price target (up previously from $74.00) on shares of PerkinElmer in a report on Tuesday, September 26th. Goldman Sachs Group, Inc. (The) reiterated a “neutral” rating and issued a $67.00 price target on shares of PerkinElmer in a report on Tuesday, September 26th. Zacks Investment Research upgraded shares of PerkinElmer from a “hold” rating to a “buy” rating and set a $74.00 target price for the company in a report on Tuesday, August 1st. Finally, Wells Fargo & Company started coverage on shares of PerkinElmer in a report on Thursday, July 13th. They set a “market perform” rating and a $72.00 price target for the company. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and six have given a buy rating to the company’s stock. PerkinElmer has an average rating of “Hold” and a consensus price target of $68.64.

Shares of PerkinElmer (NYSE:PKI) traded down $1.65 on Friday, reaching $70.62. 863,653 shares of the company traded hands, compared to its average volume of 573,270. The stock has a market capitalization of $7.94 billion, a PE ratio of 25.92 and a beta of 0.77.

PerkinElmer (NYSE:PKI) last announced its quarterly earnings data on Thursday, August 3rd. The medical research company reported $0.67 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.67. The company had revenue of $547.00 million for the quarter, compared to the consensus estimate of $554.14 million. PerkinElmer had a net margin of 18.27% and a return on equity of 13.50%. The company’s quarterly revenue was up 2.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.67 EPS. equities research analysts forecast that PerkinElmer will post 2.89 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “PerkinElmer, Inc. (PKI) Price Target Raised to $78.00 at Morgan Stanley” was reported by Community Financial News and is the property of of Community Financial News. If you are accessing this piece of content on another site, it was stolen and reposted in violation of United States & international trademark and copyright legislation. The legal version of this piece of content can be read at https://www.com-unik.info/2017/11/03/perkinelmer-inc-pki-price-target-raised-to-78-00-at-morgan-stanley.html.

A number of hedge funds have recently made changes to their positions in the business. BNP Paribas Arbitrage SA lifted its position in PerkinElmer by 59.9% during the third quarter. BNP Paribas Arbitrage SA now owns 60,638 shares of the medical research company’s stock valued at $4,182,000 after buying an additional 22,710 shares in the last quarter. Bessemer Group Inc. lifted its position in PerkinElmer by 22.2% during the third quarter. Bessemer Group Inc. now owns 27,149 shares of the medical research company’s stock valued at $1,873,000 after buying an additional 4,936 shares in the last quarter. Swiss National Bank lifted its position in PerkinElmer by 0.8% during the third quarter. Swiss National Bank now owns 184,000 shares of the medical research company’s stock valued at $12,690,000 after buying an additional 1,500 shares in the last quarter. Prudential Financial Inc. lifted its position in PerkinElmer by 6.1% during the third quarter. Prudential Financial Inc. now owns 161,133 shares of the medical research company’s stock valued at $11,114,000 after buying an additional 9,250 shares in the last quarter. Finally, USA Financial Portformulas Corp acquired a new position in PerkinElmer during the third quarter valued at approximately $3,016,000. 92.46% of the stock is currently owned by hedge funds and other institutional investors.

PerkinElmer Company Profile

PerkinElmer, Inc is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment serves the environmental, food, industrial, life sciences research and laboratory services markets.

Analyst Recommendations for PerkinElmer (NYSE:PKI)

What are top analysts saying about PerkinElmer Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for PerkinElmer Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit